Dermatology startup Dermira raises $42M in Series A and acquires Valocor Therapeutics
This article was originally published in Scrip
Dermira Inc, a new company focusing on the dermatology arena including an early-stage acne therapy candidate, has raised $42 million in a Series A round, which includes existing investor Bay City Capital, along with New Enterprise Associates and Canaan Partners. In conjunction with the fund raising, Dermira has acquired the dermatology company Velocor Therapeutics for an undisclosed sum, and it will continue to seek out other dermatological assets for licensing or acquisition.
You may also be interested in...
ChemoCentryx has successfully completed its initial public offering on Nasdaq, raising $45 million to help support its multiple R&D programmes. It sold 4.5 million shares at $10, a somewhat less ambitious debut than it had originally planned in January when it wanted to sell four million shares at $14-$16. The reduced offer is a sign of the challenging nature of the IPO market, but ChemoCentryx's assessment of its own worth was at least closer to the market’s assessment that Cempra which got its IPO away on 6 February at valuation that was less than two-thirds of that implied by its initial prospectus (scripintelligence.com, 7 February 2012).
Ampio Pharmaceuticals, a development-stage company, initially raised $15 million which was boosted to $16.9 million by the exercise of overallotments by brokers. The shares were offered at $3.25, an 8.5% discount to the closing price of $3.66 on 12 July. The market pushed them down slightly further to 3.21 on 13 July.
Verastem, a cancer stem cells startup, has moved quickly to build its pipeline just five months after an initial public offering. Management at the Cambridge, Massachusetts firm believes that recent moves have accelerated Verastem's clinical development plans by a year.